MedPath

Role of Doppler Ultrasound in Severe Peptic Ulcer Hemorrhage

Not Applicable
Terminated
Conditions
Peptic Ulcer Hemorrhage
Interventions
Device: Doppler ultrasound probe
Registration Number
NCT00164905
Lead Sponsor
Chinese University of Hong Kong
Brief Summary

The aim of study is to evaluate whether Doppler ultrasound can accurately identify patients who are at risk of recurrent bleeding, who will require endoscopic therapy, and who will fail endoscopic therapy.

Detailed Description

Bleeding peptic ulcer is a life-threatening emergency. Endoscopic therapy is a proven technique in the acute hemostasis of bleeding ulcers. Currently there is no objective assessment of adequacy of endoscopic therapy. Endoscopic Doppler ultrasound enables endoscopists in detecting blood flow in a vessel beneath an ulcer. A persistent signal after endoscopic therapy predicts recurrent bleeding. The current study proposes to compare assessment of ulcer base using either Doppler ultrasound or endoscopists' interpretation of ulcer floors. The trial design is one of a prospective randomized controlled cross-over study in which patients with severe upper gastrointestinal bleeding and documented peptic ulcers at endoscopy are enrolled.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
121
Inclusion Criteria
  • Clean base ulcer with severe upper GIB (defined as melaena, hematochezia, hematemesis, and/or gross blood in NG lavage), and any one of the following:

    1. SBP ≤ 90mmHg; P of ≥110 bpm; or orthostatic changes with SBP drops 20mmHg or P increases 20 bpm; or,
    2. Transfusion of 2 or more units of packed red blood cells within 12 hrs of admission; or,
    3. A documented HCT drop of at lest 6% from baseline.
  • Endoscopically confirmed bleeding from GU, DU, pyloric ulcer, or anastomotic ulcer

  • Pt can either have primary or secondary acute UGI haemorrhage

Read More
Exclusion Criteria
  • Bleeding site from lesion other than GU, DU, pyloric or anastomotic ulcer
  • there is more than one type of significant bleeding lesion
  • Documented hx of cirrhosis / portal HT
  • ESRF requiring any form of dialysis
  • Expected or persistent (>24hrs) coagulopathy with INR> 1.5
  • Platelet count is under 50000/mm3
  • Aspirin User / Plavix [Clopidogrel] User
  • If the ulcer is neoplastic
  • Cannot obtained consent
  • Age < 18 or is pregnant
  • Severe comorbid of which life expectancy <30 days
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Doppler ultrasoundDoppler ultrasound probe-
Primary Outcome Measures
NameTimeMethod
Recurrent bleedingWithin 30 days
Secondary Outcome Measures
NameTimeMethod
Length of stayWithin 56 days
ICU utilizationWithin 56 days
Blood Transfusion during hospitalWithin 56 days
Need for urgent/emergent ulcer surgery for bleedingWithin 56 days
Need for angiographic treatment of bleedingWithin 56 days
Deathwithin 56 days

Trial Locations

Locations (1)

Endoscopy Center, Prince of Wales Hospital

🇨🇳

Hong Kong SAR, China

© Copyright 2025. All Rights Reserved by MedPath